BeiGene Ltd ADR buy marge
Start price
06.11.17
/
50%
€83.33
Target price
01.01.19
€198.44
Performance (%)
51.83%
End price
01.01.19
€126.51
Summary
This prediction ended on 01.01.19 with a price of €126.51. With a performance of 51.83% the BUY prediction by marge was a big success. marge has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
BeiGene Ltd ADR | 18.699% | 18.699% | -37.069% | -50.340% |
iShares Core DAX® | 0.961% | -2.210% | 12.839% | 17.154% |
iShares Nasdaq 100 | 2.626% | -1.918% | 38.498% | 45.463% |
iShares Nikkei 225® | 0.217% | -7.216% | 19.425% | 5.076% |
iShares S&P 500 | 1.540% | -1.858% | 27.801% | 42.583% |
Comments by marge for this prediction
In the thread Beigene Ltd ADR diskutieren
BeiGene is a Buy, as the stock is currently over 25% off its high!
Validation came in the form of a global collaboration deal signed with Celgene to commercialize PD-1 inhibitor BGB-A137. The specifics of the deal were interesting, with BeiGene management wisely
licensing rights in China to Celgene's next generation CelMod for lymphoma and hepatocellular carcinoma, CC-122. The financial terms were very generous, with BeiGene to receive upfront licensing fees of $263 million. The larger firm purchased 32.7 million shares at $59.55 per ADS (a 35% premium over the 11-day volume-weighted average price at the time).
(Laufzeit überschritten)
Stopped prediction by marge for BeiGene Ltd ADR
BeiGene Ltd ADR
Start price
Target price
Perf. (%)
€120.88
01.01.19
01.01.19
€250.00
04.11.21
04.11.21
166.39%
05.11.21
05.11.21